ENvue Medical announced that its UroShield® Kit has been added to the UK National Health Service (NHS) Drug Tariff Part IX, creating a prescription‑based reimbursement pathway that will allow the kit to be covered nationwide in both community and hospital settings.
The inclusion removes a major reimbursement barrier and signals early commercial demand, as evidenced by a first‑time purchase order from Peak Medical, a leading UK distributor of stoma care and urology devices. The order demonstrates that NHS clinicians are ready to prescribe the kit and that the product has achieved the necessary regulatory and quality approvals to be adopted across the NHS network.
The UroShield® Kit uses low‑frequency ultrasonic energy to inhibit biofilm formation on urinary catheters, reducing the risk of catheter‑associated urinary tract infections (CAUTIs). CAUTIs affect roughly 6‑10 % of patients with indwelling catheters in the UK and cost the NHS millions of pounds in direct hospital expenses and lost quality‑adjusted life‑years. By addressing this high‑burden infection, the kit offers both clinical benefit and potential cost savings for NHS providers.
ENvue Medical, formerly NanoVibronix, has been expanding its acoustic‑based therapeutic portfolio. The UroShield Actuator was added to the NHS Drug Tariff in 2023, and the company’s rebranding reflects a broader strategy that includes the ENvue feeding‑tube placement system. CEO Doron Besser noted that the Drug Tariff inclusion “removes a major reimbursement barrier and enables scalable NHS prescribing,” while the initial order provides “early revenue visibility heading into 2026.”
The regulatory milestone and early order position ENvue to accelerate sales in the UK and serve as a precedent for expansion into other European markets where CAUTIs are common. The company now has a proven reimbursement pathway and a validated commercial channel, setting the stage for subsequent orders and broader adoption of its acoustic‑based technologies across the continent.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.